Can the AIM-listed Sareum stock price keep rising?

The Sareum stock price has risen due to excitement about potential Covid-19 treatments. I do think the company might be worth investing in, just not right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Sareum (LSE:SAR) stock price has risen 123% from 2.75p to 6.13p this month. Shares in the AIM-listed specialist drug development company have also risen in price by 1,046% over the last year. Something has obviously piqued investor interest in Sareum because before 2020, its share price was fairly flat. Of course, the pandemic has had a lot to do with raising the visibility and price of Sareum stock.

Sareum had a portfolio of developmental small molecule drugs before Covid. One had been snapped up on licence by another company to develop for the treatment of cancer. However, starting in April 2020, Sareum alerted investors to the potential of its drugs as treatments for Covid-19. This looks like it kicked off the Sareum stock price surge.

Additionally, there have been two private equity raises this month, which will in part fund Covid-19 research. This could have boosted the share price too. The high-net-worth individual who was willing to put over £2m of their money into the company was perhaps taken as a vote of confidence. Yet I can’t help but feel that investors are overvaluing Sareum’s potential Covid treatments.

Beyond Covid-19

Sareum isn’t all about Covid. It has also collaborated on the development of SRA737, a selective checkpoint kinase 1 (Chk1) inhibitor. At a meeting of the American Association for Cancer Research in April 2021, a paper was presented that suggested SRA737, combined with another company’s drug, caused cell death in cancer cell lines with a certain mutation and warrants further investigation. This mutation is present in about half of all solid cancers. US-based Sierra Oncology acquired the licence for this from Sareum in 2016. 

The SRA737 development should have been big news. Sareum is due a $2m milestone payment from Sierra when SRA737 is given to the first trial patient, and the deal has been valued at circa $290m, plus royalties, in total. However, neither the announcement of the presentation in March 2021, nor the presentation itself, specifically moved the Sareum stock price.

Sareum is also developing dual tyrosine kinase 2 (TYK2)/Janus Kinase 1 (JAK1) inhibitors. Two indications have been identified: SDC-1801 targeting autoimmune disease (and the severe inflammatory response from Covid-19) and SDC-1802 targeting cancers. Unfortunately, the Covid-19 pandemic and perhaps the focus on Covid indications have delayed the autoimmune and cancer application development.

Sareum stock price

I do think the Sareum price can rise higher in the future. However, I would not buy this stock at the moment. I think investors have overvalued the potential Covid-19 applications of its treatments. Those severe inflammatory responses — the kind that requires hospital treatment — in Covid-19 patients will become increasingly uncommon as vaccinations are rolled out and the pandemic abates.

I think interest in Sareum might wane as the pandemic fades, so I see the share price sliding in the near term. However, it has raised cash that it can use to fund research into its core indications of cancer and autoimmune disease if it abandons its Covid interests.

I will consider buying Sareum stock in my Stocks and Shares ISA once we are in a post-pandemic world. But even if I do, I am aware that Sareum has no meaningful revenue at this stage. It is a highly speculative investment whose developments could either pay off handsomely or fail.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Down 70%+ since 2020, is IAG’s share price an unmissable bargain?

IAG’s share price is still down around 73% from its pre-Covid level, but with the business performing well last year,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£17,000 of shares in the FTSE 100 dividend giant can make me £18,874 every year in passive income!

This FTSE 100 dividend superstar has an 8.8% yield with dividends projected to rise. It looks very undervalued to me…

Read more »

Investing Articles

2 top UK growth stocks I’m buying for my Stocks and Shares ISA in July

Looking for UK-listed growth firms to add to a Stocks and Shares ISA? Our writer highlights two he's planning to…

Read more »

artificial intelligence investing algorithms
Investing Articles

This overvalued growth stock makes Nvidia look cheap!

ARM Holdings is a growth stock that’s benefitted from the AI rally. Muhammad Cheema takes a look at whether this…

Read more »

Investing Articles

1 penny stock I’d buy today while it’s 63p

This penny stock's down 70% since last March, yet could be set for a big comeback as the firm rebuilds…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »